Key Insights

Highlights

Success Rate

90% trial completion (above average)

Published Results

53 trials with published results (25%)

Research Maturity

143 completed trials (69% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

7.7%

16 terminated out of 208 trials

Success Rate

89.9%

+3.4% vs benchmark

Late-Stage Pipeline

26%

55 trials in Phase 3/4

Results Transparency

37%

53 of 143 completed with results

Key Signals

53 with results90% success16 terminated

Data Visualizations

Phase Distribution

197Total
Not Applicable (88)
Early P 1 (1)
P 1 (13)
P 2 (40)
P 3 (42)
P 4 (13)

Trial Status

Completed143
Unknown19
Terminated16
Recruiting14
Not Yet Recruiting9
Active Not Recruiting3

Trial Success Rate

89.9%

Benchmark: 86.5%

Based on 143 completed trials

Clinical Trials (208)

Showing 20 of 20 trials
NCT06957691Phase 2Recruiting

Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy

NCT07729150Not ApplicableNot Yet Recruiting

Reduce HEAT: A Randomized Trial of Wearable Thermal Devices for ADT-Induced Hot Flashes

NCT07695051Not ApplicableCompleted

Effect of Cold Shower Therapy on Hot Flashes And Night Sweats in Menopausal Women

NCT06743269Not ApplicableRecruiting

Time-Efficient Inspiratory Muscle Strength Training for Reducing Sympathetic Activity and Improving Sleep in Midlife Women

NCT05587296Phase 3Active Not Recruiting

A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer

NCT07594002Not ApplicableNot Yet Recruiting

Comparing Acupuncture vs. Sham Acupuncture for the Management of Hot Flashes in Prostate Cancer Patients Receiving Hormone Therapy

NCT06440967Phase 3Active Not RecruitingPrimary

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy

NCT05193968Not ApplicableRecruitingPrimary

Hot Flashes and Neurovascular Function in Women

NCT07535541Not ApplicableRecruiting

A Feasibility Study of Biometric Measurements Via Wearable Smart Watch Technology for Evaluation of Vasomotor Symptoms in Patients Treated With Androgen Deprivation Therapy for Prostate Cancer (Prostate 007)

NCT06049797CompletedPrimary

A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats

NCT07602530RecruitingPrimary

A Study in Canada to Follow Outcomes of Women in Menopause Treated With Fezolinetant for Hot Flashes, When Given in Clinical Practice

NCT05251324RecruitingPrimary

The Cardiovascular Impact of Hot Flushes

NCT05331209Not ApplicableNot Yet RecruitingPrimary

Acupuncture With/Without Self-acupressure for Post-oophorectomy Hot Flashes in BRCA Carriers

NCT07533097Not ApplicableNot Yet RecruitingPrimary

The Effect of Cold Packs on Hot Flushes and Depression in Women Going Through the Climacteric Period

NCT06206421Phase 3CompletedPrimary

A Study to Assess Long-term Safety of Fezolinetant Given to Japanese Women Going Through Menopause

NCT06812754Phase 2CompletedPrimary

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Chinese Women Going Through Menopause

NCT07294339Not ApplicableNot Yet Recruiting

A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positive Breast Cancer

NCT07455812Active Not RecruitingPrimary

A Study in Germany to Learn About the Value of Fezolinetant in Treating Hot Flashes and Night Sweats in Women During Menopause

NCT01530373Phase 2RecruitingPrimary

Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients

NCT07422727Not ApplicableEnrolling By InvitationPrimary

Impact of Cooling Mats on Vasomotor Symptoms in Patients Receiving Endocrine Therapy

Scroll to load more

Research Network

Activity Timeline